Overview of immune checkpoint inhibitors in gynecological cancer treatment

Pirš, Boštjan (avtor), Škof, Erik (avtor), Smrkolj, Vladimir (avtor), Smrkolj, Špela (avtor)

In the last ten years, clinical oncology has been revolutionized by the introduction of oncological immunotherapy, mainly in the form of immune checkpoint inhibitors (ICIs) that transformed the standard of care of several advanced solid malignancies. Using ICIs for advanced gynecological cancers has yielded good results, especially for endometrial cancer. In ovarian or cervical cancer, combining ICIs with other established agents has shown some promise. Concurrently with the clinical development of ICIs, biomarkers that predict responses to such therapy have been discovered and used in clinical trials. The translation of these biomarkers to clinical practice was somewhat hampered by lacking assay standardization and non-comprehensive reporting of biomarker status in trials often performed on a small number of gynecological cancer patients. We can expect increased use of ICIs combined with other agents in gynecological cancer in the near future. This will create a need for reliable response prediction tools, which we believe will be based on biomarker, clinical, and tumor characteristics. In this article, we review the basic biology of ICIs and response prediction biomarkers, as well as the latest clinical trials that focus on subgroup effectiveness based on biomarker status in gynecological cancer patients.

• Jezik: Angleški jezik
• Ključne besede: immune check-point inhibitor, biomarker, endometrial cancer, ovarian cancer, uterine cervical cancer, vulvar cancer, treatment response prediction
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.02 - Pregledni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2022
• Št. strani: 24 str.
• Številčenje: Vol. 14, iss. 3, art. 631
• PID: 20.500.12556/RUL-137026
• UDK: 618.1
• ISSN pri članku: 2072-6694
• DOI: 10.3390/cancers14030631
• COBISS.SI-ID: 95979779
• Datum objave v RUL: 30.05.2022

Gradivo je del revije

• Naslov: Cancers
• Skrajšan naslov: Cancers
• Založnik: MDPI
• ISSN: 2072-6694
• COBISS.SI-ID: 517914137

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
• Začetek licenciranja: 01.02.2022

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: ginekologija, rak endometrija, biomarkerji, rak jajcevodov, rak materničnega vratu, zdravljenje

Projekti

• Financer: Drugi - Drug financer ali več financerjev
• Program financ.: University Medical Centre Ljubljana
• Številka projekta: TP20210160